SM

Scott Minick

Executive Chairman at Aira

San Francisco Bay Area

Overview 

Scott Minick is the Executive Chairman at Aira in the San Francisco Bay Area, with a background in venture capital and corporate development. He has served as CEO of BIND Therapeutics and as a Managing Director at ARCH Venture Partners, demonstrating a strong track record in strategic partnerships and commercialization within the biotech sector.

Work Experience 

  • Board Member

    2024 - Current

BPGbio is a clinical-stage biopharma company that uses AI and patient biology to de-risk and accelerate drug discovery.

Raised $480,000,000.00.

  • Advisor

    2021

Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.

Raised $257,204,774.00 from Alerce Medical Technology Partners.

  • Board Member

    2012

Beth Israel Deaconess Medical Center is a health care system that brings together academic medical centers and teaching hospitals.

Raised $5,580,652.00 from Parkinson's Foundation, BIRD Foundation, MassAITC, Society to Improve Diagnosis in Medicine and Massachusetts Life Sciences Center.

  • Member Board of Trustees

    2016 - 2022

  • Venture Partner

    2008 - 2021

  • Managing Director

    1998 - 2010

ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.

  • Executive Chairman

    2016 - 2020

Aira provides tech-enabled services for the 300 million visually impaired people around the globe.

Raised $35,565,000.00 from Bose Ventures, Arboretum Ventures, Lux Capital, ARCH Venture Partners, Felicis and Jazz Venture Partners.

  • Member Board of Directors

    2007 - 2019

  • Member Board of Directors

    2012 - 2017

Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.

Raised $257,204,774.00 from Alerce Medical Technology Partners.

  • CEO

    2010 - 2015

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.

Raised $91,847,684.00 from RUSNANO.

  • Director

    2006 - 2014

  • Director

    2006 - 2014

Articles About Scott

Relevant Websites